Capping Medicine Margins May Not Reduce Patients' Bills, Hospitals Tell Supreme Court

Capping Medicine Margins May Not Reduce Patients' Bills, Hospitals Tell Supreme Court

The Healthcare Federation of India has told the Supreme Court that capping the margins hospitals charge on medicines may not necessarily reduce patients' overall medical expenses. It argued that such restrictions could affect the financial functioning of hospitals without bringing down the total cost of treatment.

In its written submissions, the federation, which represents more than 100 hospitals and healthcare providers, opposed the proposal to regulate margins on medicines and medical consumables sold to patients. The submissions were filed in response to a petition alleging that hospitals charge excessive prices for medicines and medical supplies.

The federation argued that hospitals should not be compared with retail pharmacies or drug distributors, as the cost of medicines in hospitals also covers several services involved in their storage, preparation and administration.

It submitted that these expenses include pharmacy operations, emergency stock management, cold-chain storage, nursing support, drug preparation, administration and patient monitoring.

According to the federation, hospitals carry out nearly 29 different activities before administering chemotherapy drugs to patients. It argued that these services involve additional costs that are not reflected in the original purchase price of the medicines.

The federation further submitted that capping medicine margins would not eliminate these expenses. Hospitals may instead shift such costs to other components of patients' bills, leaving the overall treatment cost largely unchanged.

It also urged the Supreme Court to leave medicine pricing decisions to specialised regulatory authorities. In this regard, it referred to the National Pharmaceutical Pricing Authority's (NPPA) decision to cap trade margins at 30% for 137 anti-cancer medicines.

The federation also raised concerns over the proposal to determine permissible margins on the basis of procurement costs. It submitted that hospitals purchase medicines at different prices depending on the quantity ordered, suppliers and commercial arrangements. A uniform procurement-based formula, it argued, could disadvantage hospitals that negotiate better prices from manufacturers.

Defending the financial position of hospitals, the federation stated that more than 90% of their revenue is spent on operational expenses. It added that listed hospital operators generally report profit-after-tax margins of around 9-10%, compared to approximately 17.8% earned by pharmaceutical manufacturers.

The federation also highlighted the financial challenges faced by hospitals treating patients under government healthcare schemes, including Ayushman Bharat, CGHS and ECHS.

It claimed that hospitals often provide treatment under these schemes at a loss, with losses on certain government-funded treatments reaching nearly 30%. It further stated that reimbursement payments under these schemes can take more than 200 days.

Responding to an example cited by the petitioners, where a medicine allegedly purchased for around ₹2,700 was billed to a patient at approximately ₹27,000, the federation described it as an isolated instance that did not represent the general pricing practices of hospitals.

It instead referred to pricing data for major cancer drugs, including Keytruda, Darzalex and Enhertu, and submitted that their margins generally ranged between 16% and 20%.

The federation also relied on findings of the Competition Commission of India (CCI), which had found no abuse following an investigation into hospital pricing practices. It argued that comparing the purchase price of medicines with the amount charged to patients does not account for the various services and expenses involved in providing treatment.

The federation warned that imposing broad restrictions on medicine margins could discourage investment in healthcare infrastructure. It pointed out that India needs significant investment to expand hospital capacity and increase the availability of hospital beds.

Share this News

Website designed, developed and maintained by webexy